Design and Build Process of a Small Satellite Deployable UHF Antenna

This article presents a design, development, and testing process of a deployable right-hand circular polarization (RHCP) helical antenna for a small satellite in the UHF band. In the stowed configuration the antenna is 5cm and deploys to an operational length of 74cm. Deployment of the antenna is controlled by a DC motor and once released, extends to its full shape under spring power, a 3-turn jack-in-the-box design. The antenna is tuned and matched to correct frequency bandwidth and features an optical deployment confirmation circuit. The antenna produces an axial mode, with an average beamwidth of 60° and this is achieved by winding the helix to the right pitch and spacing. At range testing the antenna achieved an average gain of 7dBi through the frequency and an axial ratio of less than 3dB

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Fast Searches for Effective Optimization Phase Sequences

It has long been known that a fixed ordering of optimization phases will not produce the best code for every application. One approach for addressing this phase ordering problem is to use an ev olutionary algorithm to search for a specific sequence of phases for each module or function. While such searches have been shown to produce more efficient code, the approach can be extremely slow because the application is compiled and executed to evaluate each sequence’s effectiveness. Consequently, evolutionary or iterative compilation schemes have been promoted for compilation systems targeting embedded applications where longer compilation times may be tolerated in the final stage of development. In this paper we describe two complementary general approaches for achieving faster searches for effective optimization sequences when using a genetic algorithm. The first approach reduces the search time by avoiding unnecessary executions of the application when possible. Results indicate search time reductions of 65 % on average, often reducing searches from hours to minutes. The second approach modifies the search so fewer generations are required to achieve the same results. Measurements show that the average number of required generations decreased by 68%. These improvements have the potential for making evolutionary compilation a viable choice for tuning embedded applications

N-variant systems: A secretless framework for security through diversity

We present an architectural framework for systematically using automated diversity to provide high assurance detection and disruption for large classes of attacks. The framework executes a set of automatically diversified variants on the same inputs, and monitors their behavior to detect divergences. The benefit of this approach is that it requires an attacker to simultaneously compromise all system variants with the same input. By constructing variants with disjoint exploitation sets, we can make it impossible to carry out large classes of important attacks. In contrast to previous approaches that use automated diversity for security, our approach does not rely on keeping any secrets. In this paper, we introduce the N-variant systems framework, present a model for analyzing security properties of N-variant systems, define variations that can be used to detect attacks that involve referencing absolute memory addresses and executing injected code, and describe and present performance results from a prototype implementation. 1

Secure and practical defense against code-injection attacks using software dynamic translation

One of the most common forms of security attacks involves exploiting a vulnerability to inject malicious code into an executing application and then cause the injected code to be executed. A theoretically strong approach to defending against any type of code-injection attack is to create and use a process-specific instruction set that is created by a randomization algorithm. Code injected by an attacker who does not know the randomization key will be invalid for the randomized processor effectively thwarting the attack. This paper describes a secure and efficient implementation of instruction-set randomization (ISR) using software dynamic translation. The paper makes three contributions beyond previous work on ISR. First, we describe an implementation that uses a strong cipher algorithm—the Advanced Encryption Standard (AES), to perform randomization. AES is generally believed to be impervious to known attack methodologies. Second, we demonstrate that ISR using AES can be implemented practically and efficiently (considering both execution time and code size overheads) without requiring special hardware support. The third contribution is that our approach detects malicious code before it is executed. Previous approaches relied on probabilistic arguments that execution of non-randomized foreign code would eventually cause a fault or runtime exception